Plasmacytoma variant translocation 1 (PVT1) (PVT1)

Plasmacytoma variant translocation 1 (PVT1) is a long non-coding RNA (lncRNA) gene located at human chromosome 8q24, in close proximity to the oncogene MYC[3][4]. PVT1 itself does not encode a protein but acts as a regulatory RNA with wide-ranging effects in cancer biology. It is frequently found to be overexpressed or amplified in various human malignancies and is implicated as an oncogene. Mechanistically, PVT1 promotes cell proliferation, inhibits apoptosis, facilitates invasion and metastasis, and supports altered energy metabolism (Warburg effect), largely through acting as a molecular "sponge" for tumor-suppressive microRNAs and regulating the stability and transcriptional activity of MYC[1][2][3][4]. PVT1 can interact with chromatin remodeling factors like EZH2 and forms complexes with MYC, enhancing its oncogenic potential. Additionally, the PVT1 genomic locus can give rise to several microRNAs (e.g., miR-1204, miR-1205, etc.). High PVT1 expression is a negative prognostic marker in multiple cancers, and its inhibition in preclinical studies suppresses tumor growth and reverses chemoresistance. However, as of now, no specific drugs or therapies are FDA-approved to directly target PVT1, and efforts to exploit it therapeutically remain experimental[3][4].

Other names

NCRNA00079LINC00079onco-lncRNA-100MIR1204HGTP53LC09non-protein coding RNA 79long intergenic non-protein coding RNA 79MIR1204-MIR1207 host geneplasmacytoma variant translocation 1pvt-1 (murine) oncogene homologHLA-A24 ligand (HF10)CXCR4/PVT1 fusionvarious PVT1 gene fusion names (e.g. PVT1/MYC fusion, PVT1/CCDC26 fusion)

gene expression silencing (e.g., antisense oligonucleotides, RNA interference), inhibition of PVT1/miRNA interactions, disruption of PVT1-mediated oncogenic pathways (theoretical or preclinical)